sepantronium bromide + rituximab

A combination regimen of **sepantronium bromide** and **rituximab** is an experimental therapy that merges a targeted **survivin suppressant** small molecule (sepantronium bromide) with an **anti-CD20 monoclonal antibody** (rituximab). Sepantronium bromide induces apoptosis by selectively inhibiting survivin, a protein upregulated in multiple human cancers and associated with therapeutic resistance and aggressive disease. Rituximab targets CD20 on B-lymphocytes, leading to cell death via mechanisms that include antibody-dependent cellular cytotoxicity and complement activation. The primary theoretical indication for this combination would be high-grade B-cell malignancies or other settings where both survivin inhibition and CD20 targeting are desired; however, there is no published evidence of clinical trials specifically for this combination. Each agent has shown synergy with cytotoxic chemotherapy and is under investigation for numerous cancer types; sepantronium bromide (YM155) has been in phase I/II studies in solid tumors, while rituximab is approved for several B-cell lymphomas, leukemias, and autoimmune diseases[1][2][3][5][6][7].

Brand names

RituxanTruxima

Other names

YM-155YM155YM 155sepantroniumrituximab-abbs